Jim Cramer's Stop Trading: Regeneron Investors Should Not Freak Out

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said trading on the last day of the quarter can be tough, since fund managers are doing a lot of juggling with their positions. 

Specifically, he pointed to Regeneron (REGN) , which reported positive Phase 2 results for its chronic sinusitis drug, Dupilumab. The company is partnered with Sanofi (SNY) for this drug. 

The results, which can also be helpful in treating asthma and atopic dermatitis, should have shares of Regeneron higher by $10. However, since the overall biotech sector is lower due to it being the last day of the quarter, the stock is not reacting the same, Cramer reasoned. 

Investors shouldn't "freak out" because of the price action. It will be fine once the fourth quarter begins. Cramer said he expects the stock market to be strong next quarter, as more money continues to come into U.S. equities. 

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

2 More Reasons to Sell All Your Stocks and Run Away

2 More Reasons to Sell All Your Stocks and Run Away

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast